Nutlin-3a, an MDM2 inhibitor and a selective activator of the p53 pathway, has been shown to exhibit dose-dependent antiproliferative and cytotoxic activity in OCI-AML-3 and MOLM-13 cells with wt p53 but to produce no response in HL-60 and NB4 cells expressing mutant p53 (Haaland et al., 2014; Borthakur et al., 2015; Trino et al., 2016; Fontana et al., 2021). Here, TP53 is linked to acute myeloid leukemia.